Eye drops in bottles of 5 ml.
Active ingredient: 4-Aminobenzoic acid 70 mсg/ml, 5 ml.
Inactive ingredients: sodium chloride and water for injections.
Application and dosage
Dosage for children and adults in case of acute viral eye diseases is 1-2 drops instilled into conjunctival cavity 6-8 times a day; it is recommended to continue drug administration for 3-5 days after symptoms elimination.
Dosage in case of degenerative diseases of retina and cornea and dry eye syndrome is 1-2 drops instilled into conjunctival cavity 3-4 times a day; the duration of treatment course is to be prescribed by a doctor.
Hypersensitivity to the components of the drug. As yet, there is no data on clinical trials of the drug use during pregnancy and lactation or in children. It is recommended to administer Actipol if the benefit of the drug outweighs the risks of treatment.
Conjunctival hyperemia and local allergic reactions.
The use of Actipol in combination with antiviral nucleosides (acyclovir, ganciclovir, fludarabine phosphate, etc.) and antibiotics enhances the therapeutic effect of the drug. Do not co-administer with sulfanilamides (albutsid) or with topically acting Enkad.
Store at dark place at a temperature not higher than 40C. Do not freeze. Keep out of the reach of children.
Shelf life is 2 years.
Actipol eye drops is an antiviral, antioxidant and immunomodulating topical medicine. Its antiviral effect is mainly due to the induction of endogenous interferons. Actipol’s active ingredient is 4-Aminobenzoic acid (para-aminobenzoic acid or PABA) which is an intermediate in the synthesis of folate (one of the B vitamins) mainly used against fibrotic skin disorders. As a nutritional supplement, PABA can be used in complex therapy of fatigue, irritability, depression, weeping eczema (moist eczema), scleroderma, patchy pigment loss in skin, and premature grey hair.
Apart from having a radioprotective effect, Actipol stimulates cornea regeneration. It does not have a teratogenic, mutagenic or embryotoxic impact.
The eye drops stabilize salt and water balance of mucosa and eliminate the swelling caused by a viral infection. Actipol helps adjust to wearing contact lenses and comforts the eyes. The drug is only active on damaged or injured tissues without affecting healthy ones.
- Galbinur et al (2001) Effect of actipol on interferon level in tears (clinico-laboratory study) https://www.ncbi.nlm.nih.gov/pubmed/11845692
- Akberova et al (2001) Time course of interferon status of patients with herpetic keratitis during treatment with actipol, a new inteferon inducer https://www.ncbi.nlm.nih.gov/pubmed/11339038
- Guo et al (2001) Effects of para-aminobenzoic acid (PABA) on growth of Lactobacillus acidophilus https://www.ncbi.nlm.nih.gov/pubmed/12539490
- S Akberova (2002) New biological properties of p-aminobenzoic acid https://www.ncbi.nlm.nih.gov/pubmed/12180014/
- S Akberova (2002) Actipol in treating stromal herpetic keratitis https://www.ncbi.nlm.nih.gov/pubmed/12096527
- Jacobsen et al (2003) Para-aminobenzoic acid (PABA) used as a marker for completeness of 24 hour urine: effects of age and dosage scheduling https://www.ncbi.nlm.nih.gov/pubmed/12548308
- Lebel et al (2003) Glycine conjugation of para-aminobenzoic acid (PABA): a pilot study of a novel prognostic test in acute liver failure in children https://www.ncbi.nlm.nih.gov/pubmed/12499998
- Xavier et al (2006) The vitamin-like dietary supplement para-aminobenzoic acid enhances the antitumor activity of ionizing radiation https://www.ncbi.nlm.nih.gov/pubmed/16690434
- Akberova et al (2006) Effect of paraaminobenzoic acid on interleukine-6 production in patients with herpetic keratitis https://www.ncbi.nlm.nih.gov/pubmed/17087030
- Wegkamp et al (2007) Characterization of the Role of para-Aminobenzoic Acid Biosynthesis in Folate Production by Lactococcus lactis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1855612/
- Sharma et al (2014) Effects of para-aminobenzoic acid (PABA) form and administration mode on PABA recovery in 24-hour urine collections https://www.ncbi.nlm.nih.gov/pubmed/24183994
- Laborda et al (2019) Antifungal Metabolite p-Aminobenzoic Acid (pABA): Mechanism of Action and Efficacy for the Biocontrol of Pear Bitter Rot Disease https://www.ncbi.nlm.nih.gov/pubmed/30735380